GELSOFT PLUS - BIFURCATE
Report
- Report Number
- 9612515-2012-00020
- Event Type
- Other
- Date Received
- November 30, 2012
- Date of Event
- May 24, 2012
- Report Date
- November 26, 2012
- Manufacturer
- VASCUTEK LTD.
- Product Code
- DSY
- PMA / PMN Number
- K955230
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FR
- Reporter Occupation
- PHYSICIAN
Narratives
METHOD - NO INSPECTION AND EVAL OF THE DEVICE HAS BEEN POSSIBLE AS THE EXPLANTED SECTION OF GRAFT IS CURRENTLY EN-ROUTE TO VASCUTEK. RESULTS - AS NO PRODUCT IS CURRENTLY AVAILABLE FOR INSPECTION AND EVAL A REVIEW OF THE MFG RECORDS ASSOCIATED WITH THE AFFECTED PRODUCT (GELSOFT PLUS VASCULAR PROSTHESIS, LOT NO 1117411 3020, S/N (B)(4)) WAS UNDERTAKEN; THIS CONFIRMED THAT THE PRODUCT WAS MANUFACTURED WITHIN SPECS. CONCLUSION CODE - NO CONCLUSION CAN BE DRAWN. AS NO PRODUCT HAS BEEN RETURNED FOR INSPECTION AND EVAL TO DATE, THE ROOT CAUSE OF THE REPORTED DEFECT COULD NOT BE ESTABLISHED AT THIS TIME. ONCE THE SECTION OF GRAFT HAS BEEN RETURNED TO VASCUTEK; AND OUR INSPECTION AND EVAL PROCESS IS COMPLETE, A F/U INCIDENT REPORT WILL BE ISSUED.
VASCUTEK HAS BEEN NOTIFIED OF AN INCIDENT VIA OUR (B)(4) DISTRIBUTOR (VASCUTEK (B)(4)); THAT OCCURRED IN THE (B)(6) ON (B)(6) 2012. OF NOTE VASCUTEK WAS NOT INFORMED OF THE INCIDENT UNTIL (B)(6) 2012. THE INCIDENT WAS DESCRIBED AS FOLLOWS: DR. (B)(6) PERFORMED AN ELECTIVE SURGICAL PROCEDURE TO IMPLANT A GELSOFT PLUS BIFURCATE GRAFT TO A PT. DURING THE PROCEDURE, THE SURGEON ENCOUNTERED POROSITY ISSUES (LEAKAGE) IN THE MAIN BODY AND THE LEFT LEG OF THE GRAFT. THE SURGEON ATTEMPTED TO STOP THE LEAKAGE BY USING ADD'L GAUZE AND BY USING SURGICAL (BIO-GLUE). A SECTION OF THE GRAFT WAS REMOVED AND WILL BE SENT BACK TO VASCUTEK FOR INSPECTION AND EVAL.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | GELSOFT PLUS - BIFURCATE | VASCULAR PROSTHESIS | DSY | VASCUTEK LTD. | NA | 117411 3020 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | Required Intervention |